Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma

[1]  C. Larsson,et al.  The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas , 2014, Oncogene.

[2]  F. Galateau-Sallé,et al.  Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma , 2014, Oncogene.

[3]  M. Knowles,et al.  Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. , 2014, European urology.

[4]  K. Hemminki,et al.  TERT promoter mutations in cancer development. , 2014, Current opinion in genetics & development.

[5]  T. Ørntoft,et al.  Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. , 2014, European urology.

[6]  Chang-Jiun Wu,et al.  Why is melanoma so metastatic? , 2014, Pigment cell & melanoma research.

[7]  K. Kinzler,et al.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. , 2013, Cancer research.

[8]  N. Perdigones,et al.  Telomere biology and translational research. , 2013, Translational research : the journal of laboratory and clinical medicine.

[9]  Michael E. Egger,et al.  Outcomes and prognostic factors in superficial spreading melanoma. , 2013, American journal of surgery.

[10]  K. Ichimura,et al.  TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas , 2013, Acta Neuropathologica.

[11]  David T. W. Jones,et al.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.

[12]  J. Zucman‐Rossi,et al.  Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.

[13]  D. Schadendorf,et al.  TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism , 2013, Proceedings of the National Academy of Sciences.

[14]  V. Tergaonkar,et al.  Telomerase: central regulator of all of the hallmarks of cancer. , 2013, Trends in biochemical sciences.

[15]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[16]  M. Ruden,et al.  Novel anticancer therapeutics targeting telomerase. , 2013, Cancer treatment reviews.

[17]  Stephen C. J. Parker,et al.  Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma , 2013, Proceedings of the National Academy of Sciences.

[18]  Miguel Melo,et al.  Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.

[19]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[20]  R. Tothill,et al.  BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage , 2013, Clinical Cancer Research.

[21]  T. Chan,et al.  Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. , 2013, The Journal of clinical endocrinology and metabolism.

[22]  N. Papadopoulos.  Abstract IA04: ATRX mutations in human carcinogenesis , 2013 .

[23]  K. Ichimura,et al.  Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss , 2013, Acta Neuropathologica.

[24]  R. Sullivan,et al.  Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.

[25]  G. Montgomery,et al.  NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. , 2013, The Journal of investigative dermatology.

[26]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[27]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[28]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[29]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[30]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[31]  R. Scolyer,et al.  Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma , 2012, Annals of surgery.

[32]  Gerald C. Chu,et al.  Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases , 2012, Cell.

[33]  I. Osman,et al.  Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model , 2012, Melanoma research.

[34]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[35]  R. Scolyer,et al.  BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site , 2011, Pigment cell & melanoma research.

[36]  M. Blasco,et al.  Telomere rejuvenation during nuclear reprogramming. , 2010, Current opinion in genetics & development.

[37]  D. Schadendorf,et al.  Melanocortin receptor 1 variants and melanoma risk: A study of 2 European populations , 2009, International journal of cancer.

[38]  E. Nagore,et al.  Perfil clínico y epidemiológico de los pacientes con melanoma cutáneo según el grado de exposición solar de la localización del melanoma , 2009 .

[39]  M. Mazumdar,et al.  Changes in the presentation of nodular and superficial spreading melanomas over 35 years , 2008, Cancer.

[40]  D. Peeper,et al.  BRAFE600 in benign and malignant human tumours , 2008, Oncogene.

[41]  Ole Winther,et al.  JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update , 2007, Nucleic Acids Res..

[42]  E. Blackburn,et al.  Genes and pathways downstream of telomerase in melanoma metastasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Hemminki,et al.  BRAF mutations are common somatic events in melanocytic nevi. , 2004, The Journal of investigative dermatology.

[44]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[45]  W. Hahn,et al.  Telomerase Maintains Telomere Structure in Normal Human Cells , 2003, Cell.

[46]  J. Shay,et al.  Telomerase and cancer. , 2001, Human molecular genetics.

[47]  J. Spinelli,et al.  Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Similarities to melanoma: the Vancouver Mole Study. , 1990, Archives of dermatology.

[48]  渡邉 徹心.  Novel morphological study of solar lentigines by immunohistochemical and electron microscopic evaluation , 2014 .

[49]  N. Bhatia.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis , 2012 .

[50]  A. Martorell,et al.  [Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site]. , 2009, Actas dermo-sifiliograficas.